Nature Medicine retracted a high-profile Chinese lung cancer paper that reported survival gains when immunotherapy was administered before 3 p.m., citing loss of confidence in the integrity of the results. The decision comes after scrutiny from researchers and discrepancies raised publicly, including concerns about randomization patterns and protocol differences between Chinese and English versions. The paper’s claims had drawn broad attention because they implied a potentially practice-altering, low-burden scheduling effect. Editors said the available evidence no longer supported the original conclusions, and the retraction note points to unexpected data patterns and additional concerns. For the biotech field, the retraction adds to the immediate compliance and evidence-quality focus as clinical development and biomarker strategies often depend on reproducible dataset integrity and accurate recordkeeping.